FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954298172> ?p ?o ?g. }

• W2954298172 endingPage "969" @default.
• W2954298172 startingPage "958" @default.
• W2954298172 abstract "Stereotactic ablative radiotherapy (SABR) is an emerging treatment option for primary renal cell carcinoma (RCC).To systematically review the literature on SABR for primary RCC and perform a meta-analysis evaluating local control (LC), toxicity, and renal function.A PROSPERO-registered (#115573), Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA)-based systematic review of the literature was conducted (1995-2019). Studies of SABR targeting primary RCC tumors were included, while those targeting only metastases were excluded. The primary outcome was LC defined as tumor size reduction and/or absence of local progression. Secondary outcomes included toxicity (Common Terminology Criteria for Adverse Events) and renal function (change in estimated glomerular filtration rate [eGFR]). Weighted random-effect meta-analyses using the DerSimonian and Laird method were conducted for primary and secondary outcomes. The I2 statistic and Cochran's Q test were used to assess heterogeneity.From 2386 PubMed entries and 924 meeting abstracts, 26 studies were identified (11 prospective trials), including 383 tumors in 372 patients, most of whom were deemed inoperable. Weighted averages (ranges) of median follow-up, median age, and mean tumor size were 28.0 (5.8-79.2)mo, 70.4 (62-83)yr, and 4.6 (2.3-9.5)cm, respectively. RCC histology was confirmed in 78.9% of patients who underwent pretreatment biopsy. Dose fractionation varied, but 26Gy in one fraction and 40Gy in five fractions were most common. The random-effect estimates for LC, grade 3-4 toxicity, and post-SABR eGFR change were 97.2% (95% confidence interval [CI]: 93.9-99.5%, I2=20%), 1.5% (95% CI: 0-4.3%, I2=0%), and -7.7ml/min (95% CI: -12.5 to -2.8, I2=2%), respectively, and heterogeneity was minimal. Six patients with pre-existing renal dysfunction (2.9%) required dialysis.Renal SABR is locally effective and associated with low toxicity rates for primary RCC, despite treatment of larger tumors in older, mostly medically inoperable patients.Stereotactic ablative radiotherapy is a high-precision, noninvasive radiation treatment requiring few outpatient visits, and represents a safe and effective management option for primary renal cell carcinoma." @default.
• W2954298172 created "2019-07-12" @default.
• W2954298172 creator A5006660870 @default.
• W2954298172 creator A5007170568 @default.
• W2954298172 creator A5007941548 @default.
• W2954298172 creator A5017716856 @default.
• W2954298172 creator A5037000397 @default.
• W2954298172 creator A5038486476 @default.
• W2954298172 creator A5039156745 @default.
• W2954298172 creator A5055762904 @default.
• W2954298172 creator A5078402900 @default.
• W2954298172 creator A5080126509 @default.
• W2954298172 creator A5081837886 @default.
• W2954298172 creator A5083273831 @default.
• W2954298172 creator A5083886265 @default.
• W2954298172 creator A5085787232 @default.
• W2954298172 creator A5089897569 @default.
• W2954298172 creator A5090754156 @default.
• W2954298172 creator A5091833311 @default.
• W2954298172 date "2019-11-01" @default.
• W2954298172 modified "2023-10-16" @default.
• W2954298172 title "The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis" @default.
• W2954298172 cites W1529517881 @default.
• W2954298172 cites W1592964109 @default.
• W2954298172 cites W1822261498 @default.
• W2954298172 cites W1988227725 @default.
• W2954298172 cites W1989181213 @default.
• W2954298172 cites W1994435768 @default.
• W2954298172 cites W1994704117 @default.
• W2954298172 cites W2018876835 @default.
• W2954298172 cites W2033295431 @default.
• W2954298172 cites W2043013527 @default.
• W2954298172 cites W2071275751 @default.
• W2954298172 cites W2076676662 @default.
• W2954298172 cites W2084505101 @default.
• W2954298172 cites W2087887230 @default.
• W2954298172 cites W2107328434 @default.
• W2954298172 cites W2110413848 @default.
• W2954298172 cites W2115646671 @default.
• W2954298172 cites W2123524595 @default.
• W2954298172 cites W2127267941 @default.
• W2954298172 cites W2129706387 @default.
• W2954298172 cites W2134242733 @default.
• W2954298172 cites W2134528893 @default.
• W2954298172 cites W2142294849 @default.
• W2954298172 cites W2148720699 @default.
• W2954298172 cites W2151681186 @default.
• W2954298172 cites W2152932297 @default.
• W2954298172 cites W2160396110 @default.
• W2954298172 cites W2162427240 @default.
• W2954298172 cites W2269278770 @default.
• W2954298172 cites W2310070191 @default.
• W2954298172 cites W2345180720 @default.
• W2954298172 cites W2515253554 @default.
• W2954298172 cites W2519254806 @default.
• W2954298172 cites W2580660759 @default.
• W2954298172 cites W2587017049 @default.
• W2954298172 cites W2604156953 @default.
• W2954298172 cites W2607063233 @default.
• W2954298172 cites W2612074997 @default.
• W2954298172 cites W2652023138 @default.
• W2954298172 cites W2686511444 @default.
• W2954298172 cites W2745590151 @default.
• W2954298172 cites W2796448000 @default.
• W2954298172 cites W2805746404 @default.
• W2954298172 cites W2851061510 @default.
• W2954298172 cites W2884436187 @default.
• W2954298172 cites W2884568270 @default.
• W2954298172 cites W2886508785 @default.
• W2954298172 cites W2892325025 @default.
• W2954298172 cites W2896352211 @default.
• W2954298172 cites W2906733322 @default.
• W2954298172 cites W2907719701 @default.
• W2954298172 cites W2916816608 @default.
• W2954298172 cites W3023480357 @default.
• W2954298172 doi "https://doi.org/10.1016/j.euf.2019.06.002" @default.
• W2954298172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31248849" @default.
• W2954298172 hasPublicationYear "2019" @default.
• W2954298172 type Work @default.
• W2954298172 sameAs 2954298172 @default.
• W2954298172 citedByCount "62" @default.
• W2954298172 countsByYear W29542981722020 @default.
• W2954298172 countsByYear W29542981722021 @default.
• W2954298172 countsByYear W29542981722022 @default.
• W2954298172 countsByYear W29542981722023 @default.
• W2954298172 crossrefType "journal-article" @default.
• W2954298172 hasAuthorship W2954298172A5006660870 @default.
• W2954298172 hasAuthorship W2954298172A5007170568 @default.
• W2954298172 hasAuthorship W2954298172A5007941548 @default.
• W2954298172 hasAuthorship W2954298172A5017716856 @default.
• W2954298172 hasAuthorship W2954298172A5037000397 @default.
• W2954298172 hasAuthorship W2954298172A5038486476 @default.
• W2954298172 hasAuthorship W2954298172A5039156745 @default.
• W2954298172 hasAuthorship W2954298172A5055762904 @default.
• W2954298172 hasAuthorship W2954298172A5078402900 @default.
• W2954298172 hasAuthorship W2954298172A5080126509 @default.
• W2954298172 hasAuthorship W2954298172A5081837886 @default.
• W2954298172 hasAuthorship W2954298172A5083273831 @default.

• next